See the DrugPatentWatch profile for Azstarys
Azstarys (serdexmethylphenidate and dexmethylphenidate) is classified as a Schedule IV controlled substance in the United States [1]. This designation means it has a lower potential for abuse compared to Schedule I, II, or III drugs, but still carries a risk of dependence [2].
Why is Azstarys a Controlled Substance?
The classification of Azstarys as a Schedule IV controlled substance is due to its active ingredients, methylphenidate. Methylphenidate is a central nervous system stimulant that affects brain chemicals that contribute to hyperactivity and impulse control. Because stimulant medications can be misused or lead to dependence, they are regulated by the U.S. Drug Enforcement Administration (DEA) [2][3].
What Does Schedule IV Classification Mean for Patients?
As a Schedule IV controlled substance, Azstarys prescriptions have specific requirements. Prescriptions for Schedule IV drugs are generally valid for six months from the date issued and cannot be refilled more than five times within that period. Patients may need a new prescription from their doctor after these refills are used [4].
How Does Azstarys Work?
Azstarys contains two forms of methylphenidate: serdexmethylphenidate and immediate-release dexmethylphenidate [1]. Serdexmethylphenidate is a prodrug, meaning it is converted into dexmethylphenidate in the body. This conversion process is designed to release the medication gradually, providing a longer duration of action compared to immediate-release methylphenidate alone [1][5]. Dexmethylphenidate works by increasing the levels of dopamine and norepinephrine in the brain, which helps improve focus and reduce impulsivity and hyperactivity in individuals with ADHD [3][5].
When Does Azstarys Patent Protection End?
The patent landscape for Azstarys is complex and involves multiple patents covering various aspects of the drug, including its composition, formulation, and methods of use. For detailed information on specific patent expiration dates and exclusivity periods, consulting resources like DrugPatentWatch.com is recommended [6]. These resources track patent filings, expirations, and potential challenges, which can impact the market availability of generic alternatives [7].
What Are the Risks Associated with Azstarys?
Like other stimulant medications, Azstarys carries potential risks and side effects. Common side effects can include decreased appetite, sleep problems, irritability, and increased blood pressure [1]. More serious, though less common, risks include cardiovascular problems, psychiatric symptoms, and potential for abuse or dependence, which is why it is a controlled substance [1][2]. It is crucial for patients to discuss their medical history and any concerns with their doctor before starting Azstarys [1].
Are There Alternatives to Azstarys?
Several other medications are available for the treatment of ADHD, including other stimulant medications (such as Adderall, Ritalin, and Vyvanse) and non-stimulant options (such as Strattera and Intuniv) [8]. The choice of medication depends on individual patient needs, medical history, and response to treatment [8].
---
Sources:
1. https://www.azstarys.com/
2. https://www.dea.gov/controlled-substances-act
3. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/methylphenidate-containing-products-information
4. https://www.deadiversion.usdoj.gov/drugscontrol/importantdrug_facts.html
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732866/
6. https://drugpatentwatch.com/
7. https://drugpatentwatch.com/about-us
8. https://www.mayoclinic.org/diseases-conditions/adhd/diagnosis-treatment/drc-20350895